

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cryofocus Medtech (Shanghai) Co., Ltd.

康灃生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

**(1) POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING
HELD ON JUNE 20, 2025; AND
(2) AMENDMENTS TO ARTICLES OF ASSOCIATION**

The Board is pleased to announce that all the proposed resolutions as set out in the AGM Notice were duly passed by the Shareholders by way of poll at the AGM.

Reference is made to the notice (the “**AGM Notice**”) and the circular (the “**Circular**”) of the 2024 annual general meeting (the “**AGM**”) of Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”) both dated April 29, 2025. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The AGM was convened at 10:00 a.m. on Friday, June 20, 2025 at 3rd Floor, Building 25, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, the PRC. The AGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and was chaired by Mr. ZHU Jun, an executive Director and the general manager of the Company.

ATTENDANCE AT THE AGM

As at the date of the AGM, the total number of issued Shares was 239,110,000 Shares, comprising 143,438,579 H Shares and 95,671,421 Unlisted Shares. The holders of all such Shares were entitled to attend and vote for or against or abstain from voting on all the resolutions proposed at the AGM. Shareholders holding an aggregate of 138,125,947 Shares (comprising 46,991,680 H Shares and 91,134,267 Unlisted Shares), representing approximately 57.77% of the total issued Shares, attended the AGM either in person or by proxy.

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the Shareholders to attend and abstain from voting in favor of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM; and (3) no Shareholder has stated his/her/its intention to vote against or to abstain from voting on any of the resolutions proposed at the AGM. There were no Shares actually voted but excluded from calculating the poll results of the resolutions proposed at the AGM.

All the proposed resolutions as set out in the AGM Notice were voted by way of poll at the AGM. The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, and the Company acted as the scrutineers at the AGM for the purpose of vote-taking.

All Directors, namely, Mr. LI Kejian, Mr. ZHU Jun, Mr. LIU Wei, Mr. LV Shiwen, Mr. ZHAO Chunsheng, Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan, attended the AGM either in person or through electronic means.

POLL RESULTS OF THE AGM

The poll results in respect of the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of Votes (Approximate Percentage of the Total Number of Votes Cast)		
		For	Against	Abstain
1.	To consider and approve the work report of the Board for 2024.	138,125,947 (100%)	0 (0%)	0 (–)
2.	To consider and approve the work report of the Board of Supervisors for 2024.	138,125,947 (100%)	0 (0%)	0 (–)
3.	To consider and approve the profit distribution plan for 2024.	138,125,947 (100%)	0 (0%)	0 (–)
4.	To consider and approve the audited consolidated financial statements of the Group for 2024.	138,125,947 (100%)	0 (0%)	0 (–)
5.	To consider and approve the annual report of the Company for 2024.	138,125,947 (100%)	0 (0%)	0 (–)
6.	To authorize the Board to determine the remuneration of the Directors.	138,125,947 (100%)	0 (0%)	0 (–)
7.	To authorize the Board of Supervisors to determine the remuneration of the Supervisors.	138,125,947 (100%)	0 (0%)	0 (–)
8.	To consider and approve the re-appointment of Ernst & Young as the auditors of the Company for a term until the conclusion of the next annual general meeting of the Company and to authorize the Board to determine its remuneration.	138,125,947 (100%)	0 (0%)	0 (–)
As more than half of the votes were cast in favor of each of the resolutions numbered 1 to 8, all the above resolutions were duly passed as ordinary resolutions.				

Special Resolutions		Number of Votes (Approximate Percentage of the Total Number of Votes Cast)		
		For	Against	Abstain
9.	To grant a general mandate to the Board to allot, issue and deal with additional Shares (the full text of the resolution is set out in the AGM Notice).	138,125,947 (100%)	0 (0%)	0 (–)
10.	To consider and approve the proposed amendments to the Articles of Association.	138,125,947 (100%)	0 (0%)	0 (–)
As more than two-thirds of the votes were cast in favor of the resolutions numbered 9 and 10, both of the above resolutions were duly passed as special resolutions.				

Note: Pursuant to the Articles of Association, an abstention, or an abstention from voting, shall not be counted in computing the result of that vote.

AMENDMENTS TO ARTICLES OF ASSOCIATION

The proposed resolution on the amendments to the Articles of Association was duly passed at the AGM, and the proposed amendments to the Articles of Association have become effective from the date of the AGM. The revised Articles of Association will also be published on the websites of the Stock Exchange and the Company.

By Order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, June 20, 2025

As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.